Back to Search
Start Over
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021), Journal for immunotherapy of cancer, vol. 9, no. 2, pp. e001701
- Publication Year :
- 2020
- Publisher :
- BMJ, 2020.
-
Abstract
- BackgroundTalimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and demonstrated an overall response rate (ORR) of 40.5% and a complete response (CR) rate of 16.6%.ObjectivesThe aim of this study was to assess the outcome of melanoma patients treated with T-VEC in a real-life clinical setting.MethodsBased on data from 10 melanoma centers in Austria, Switzerland and southern Germany, we conducted a retrospective chart review, which included 88 patients (44 male, 44 female) with a median age of 72 years (range 36–95 years) treated with T-VEC during the period from May 2016 to January 2020.Results88 patients fulfilled the inclusion criteria for analysis. The ORR was 63.7%. 38 patients (43.2%) showed a CR, 18 (20.5%) had a partial response, 8 (9.1%) had stable disease and 24 (27.3%) patients had a progressive disease. The median treatment period was 19 weeks (range: 1–65), an average of 11 doses (range: 1–36) were applied. 39 (45.3%) patients developed adverse events, mostly mild, grade I (64.1%).ConclusionThis real-life cohort treatment with T-VEC showed a high ORR and a large number of durable CRs.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Cancer Research
Metastatic lesions
Immunology
610 Medicine & health
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Immunology and Allergy
1306 Cancer Research
Stage (cooking)
Adverse effect
RC254-282
Pharmacology
2403 Immunology
business.industry
Melanoma
10177 Dermatology Clinic
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Treatment period
ddc
Adult
Aged
Aged, 80 and over
Biological Products/adverse effects
Biological Products/therapeutic use
Disease Progression
Europe
Female
Herpesvirus 1, Human/immunology
Herpesvirus 1, Human/pathogenicity
Humans
Male
Melanoma/immunology
Melanoma/pathology
Melanoma/therapy
Middle Aged
Neoplasm Staging
Oncolytic Viruses/immunology
Oncolytic Viruses/pathogenicity
Retrospective Studies
Skin Neoplasms/immunology
Skin Neoplasms/pathology
Skin Neoplasms/therapy
Skin Neoplasms/virology
Time Factors
Treatment Outcome
immunotherapy
melanoma
oncolytic virotherapy
oncolytic viruses
030104 developmental biology
3004 Pharmacology
Oncology
030220 oncology & carcinogenesis
1313 Molecular Medicine
Cohort
2723 Immunology and Allergy
Molecular Medicine
2730 Oncology
business
Talimogene laherparepvec
Progressive disease
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021), Journal for immunotherapy of cancer, vol. 9, no. 2, pp. e001701
- Accession number :
- edsair.doi.dedup.....ed27d867e0f6ae9e5fa254d7177dae2c